These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 22826702)

  • 1. A changing landscape in castration-resistant prostate cancer treatment.
    Felici A; Pino MS; Carlini P
    Front Endocrinol (Lausanne); 2012; 3():85. PubMed ID: 22826702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer.
    George DJ; Kantoff PW; Lin DW
    Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
    Bitting RL; Armstrong AJ; George DJ
    Clin Med Insights Oncol; 2011; 5():325-32. PubMed ID: 22084621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases.
    Wen L; Valderrama A; Costantino ME; Simmons S
    Am Health Drug Benefits; 2019 May; 12(3):142-149. PubMed ID: 31346366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
    El-Amm J; Aragon-Ching JB
    Ther Adv Med Oncol; 2013 Jan; 5(1):25-40. PubMed ID: 23323145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging novel therapies for advanced prostate cancer.
    Osanto S; Van Poppel H
    Ther Adv Urol; 2012 Feb; 4(1):3-12. PubMed ID: 22295041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment strategies for castration-resistant prostate cancer.
    Kim SJ; Kim SI
    Korean J Urol; 2011 Mar; 52(3):157-65. PubMed ID: 21461278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs.
    Turco F; Gillessen S; Cathomas R; Buttigliero C; Vogl UM
    Res Rep Urol; 2022; 14():339-350. PubMed ID: 36199275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updates on therapeutic targets and agents in castration-resistant prostate cancer.
    Bishr M; Lattouf JB; Gannon PO; Saad F
    Minerva Urol Nefrol; 2011 Jun; 63(2):131-43. PubMed ID: 21623331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of metastatic castration-resistant prostate cancer.
    Antonarakis ES
    Eur Urol Rev; 2011; 6(2):90-96. PubMed ID: 23789039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.